The innovative nature and competitive strengths of our drug candidates have attracted partnerships with leading industry players and venture capitals
Joint Venture
We form a joint venture with the selected venture capital firm to consolidate resources, technology, and expertise, propelling the advancement of drug development and innovation. The NewCo serves as an independent platform for creating cutting-edge pharmaceuticals and biotherapies. By effectively distributing R&D risks, we expedite the introduction of scientific breakthroughs and enhance the therapeutic landscape for patients.
Out-Licensing
We grant the licensee the rights to use our product, technology, or intellectual property. In return, we receive royalties, upfront fees, and milestone payments from the licensee. Out-licensing enables us to generate revenue from our pipeline assets, leverage the licensee’s expertise, and enter new markets through the licensee’s established presence.
Collaborative Development
We enter into a co-development arrangement with our partner to share resources and technology, accelerating the development and commercialization of innovative pharmaceuticals, leveraging each other’s expertise to drive biotechnology breakthroughs. This collaboration not only spreads our R&D risks but also swiftly brings revolutionary treatments to patients, bolstering our market competitiveness.
Global Partner
Cooperation for providing patients with better treatment options
Leads Biolabs grants Oblenio Bio, a NewCo formed by Aditum Bio, an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody.
Leads Biolabs grants BeiGene exclusive worldwide rights, excluding Greater China for the development, manufacturing, and commercialization of LBL-007, a novel humanized anti-lag3 antibody.
Leads Biolabs and BioneCure will jointly develop world-leading ADC new drugs, aiming to provide better treatments for cancer patients.
